TY - JOUR
T1 - Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients
AU - Papaldo, Paola
AU - Di Cosimo, Serena
AU - Ferretti, Gianluigi
AU - Vici, Patrizia
AU - Marolla, Paolo
AU - Carlini, Paolo
AU - Fabi, Alessandra
AU - Cognetti, Francesco
PY - 2004
Y1 - 2004
N2 - To improve chemotherapy dose intensity and to optimize the use of granulocyte-colony stimulating factor, 506 patients with early breast cancer were randomly assigned to high dose epirubicin and cyclophospamide (EC) with or without prophylactic subcutaneously filgrastim, according to 5 different schedules: 480 μg or 300 μg daily or every other day, on day 8 through day 14, and 300 μg daily on days 8 and 12 of each chemotherapy course, Serum levels of lactate dehydrogenase (LDH) and alkaline phosphatase (AP) were significantly higher in patients given EC plus filgrastim than EC alone (P = 0.0001), the rate of G1-3 toxicity being 33.4% and 13.1% vs. 1.6% and 1%, respectively. No clinical evidence of filgrastim-related hepatic damage or significant difference in transaminase and γ-GT elevation was seen between the two groups. LDH and AP closely resembled peripheral blood leukocytes count and increased with increasing leucocytosis, throughout the 5 schedules. Although no patient continued treatment for filgrastim-related side effects, and LDH and AP rises resolved spontaneously within 3 weeks following the chemotherapy course, physicians should be aware of the transient and innocuous change in serum chemistry associated to leucocytosis, since it could be misinterpreted as expression of disease activity.
AB - To improve chemotherapy dose intensity and to optimize the use of granulocyte-colony stimulating factor, 506 patients with early breast cancer were randomly assigned to high dose epirubicin and cyclophospamide (EC) with or without prophylactic subcutaneously filgrastim, according to 5 different schedules: 480 μg or 300 μg daily or every other day, on day 8 through day 14, and 300 μg daily on days 8 and 12 of each chemotherapy course, Serum levels of lactate dehydrogenase (LDH) and alkaline phosphatase (AP) were significantly higher in patients given EC plus filgrastim than EC alone (P = 0.0001), the rate of G1-3 toxicity being 33.4% and 13.1% vs. 1.6% and 1%, respectively. No clinical evidence of filgrastim-related hepatic damage or significant difference in transaminase and γ-GT elevation was seen between the two groups. LDH and AP closely resembled peripheral blood leukocytes count and increased with increasing leucocytosis, throughout the 5 schedules. Although no patient continued treatment for filgrastim-related side effects, and LDH and AP rises resolved spontaneously within 3 weeks following the chemotherapy course, physicians should be aware of the transient and innocuous change in serum chemistry associated to leucocytosis, since it could be misinterpreted as expression of disease activity.
KW - AP
KW - Breast cancer
KW - G-CSF
KW - LDH
UR - http://www.scopus.com/inward/record.url?scp=8644269489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8644269489&partnerID=8YFLogxK
U2 - 10.1081/CNV-200027175
DO - 10.1081/CNV-200027175
M3 - Article
C2 - 15565824
AN - SCOPUS:8644269489
VL - 22
SP - 650
EP - 653
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 4
ER -